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The proﬁbrogenic role of endothelin-1 (ET-1) and angiotensin-II (AT-II) in renal ﬁbrosis 
remains disputed.  We therefore studied the effect of ET-1 and AT-II on rat mesangial 
cells (CRL-2573), the major source of extracellular matrix proteins in the kidney.  ET-1 
stimulated DNA synthesis assessed by BrdU uptake in microtiter tetrazolium assay in a 
dose dependent manner, but AT-II did not.  Proliferation of the mesangial cells by ET-1 
was suppressed by 15% with BQ123, an endothelin receptor A antagonist, which sug-
gested a signiﬁcant role of the endothelin receptor A on growth stimulation.  In the me-
sangial cells, ET-1 increased the mRNA expressions of procollagen α1 (I), transforming 
growth factor-β1, connective tissue growth factor, tissue inhibitor of metalloproteinase-1 
and matrix metalloproteinase-13 in dose dependent manners, whereas AT-II had exerted 
no effect on the expression of these mRNAs.  These data suggested that ET-1 might be 
involved in renal ﬁbrosis through the mesangial cell proliferation and/or the increase in 
ﬁbrogenic cytokines.
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Renal fibrosis and nephrosclerosis are patho-
logical states common to nephropathy of vari-
ous types, such as glomerulonephritis, diabetic 
nephropathy and hypertensive nephropathy.  In 
various diseases, accumulation of extracellular 
matrix, that is, progression of renal ﬁbrosis causes 
further deterioration of renal function (Sun et al., 
2000; Boffa et al., 2003).  It has become increas-
ingly clear that various cytokines and vasoactive 
factors are involved in extracellular matrix ac-
cumulation (Eddy, 2000; Yao et al., 2001; Mishra 
et al., 2003).  Among the vasoactive factors, 
endothelin-1 (ET-1) and angiotensin-II (AT-II) 
have potent vascular smooth muscle-contracting 
activity (Yanagisawa et al., 1988), and promote 
cell proliferation and protein synthesis.  Indeed, 
overexpression of ET-1 in transgenic mice causes 
renal interstitial fibrosis (Hocher et al., 1997), 
glomerulosclerosis (Herman et al., 1998; Hocher 
et al., 1997), renal cyst formation (Hocher et al., 
1997, 2003), and arteriolosclerosis (Boffa et al., 
2001, 2003).  By contrast, ET-1 antagonists atten-
uate progressive glomerulosclerosis in vivo (Boffa 
et al., 1999, 2001; Yao et al., 2001).  Similarly, 
AT-II plays an important role in the development 
of renal ﬁbrosis (Sun et al., 2000; Mezzano et al., 
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2001; Boffa et al., 2003).  Rats chronically infused 
with AT-II develop tubulointestitial injuries with 
tubular atrophy and dilation, cast formation and 
intestinal ﬁbrosis (Hocher et al., 1997; Mezzano et 
al., 2001).  It has been shown that ET-1 and AT-II 
are involved in the progression of various patho-
logical states, such as acute renal failure, chronic 
renal failure and chronic heart failure (Benigni 
et al., 2000; Muller et al., 2002).  However, much 
of their association with renal matrix metabolism 
remains unclear.  In this study, we examined the 
effects of ET-1 and AT-II on cell proliferation and 
matrix metabolism in mesangial cells, which are 
the main cells producing extracellular matrix in 
the kidney (Schnaper et al., 1996; Yao et al., 2001; 
Sorokin et al., 2003).
Materials and Methods
Materials
CRL-2573, a rat mesangial cell line was pur-
chased from ATCC (Manassas, VA).  BQ123, an 
antagonist for endothelin A receptor (ETAR), 
and BQ788, for endothelin B receptor (ETBR), 
as well as ET-1, were purchased from Alexis 
Biochemicals (San Diego, CA).  A bromodeoxy-
uridine (BrdU) colorimetric cell proliferation 
enzyme-linked immunosorbent assay kit was 
purchased from (Roche Diagnostics, Mannheim, 
Germany).  A cell count kit-8 was purchased from 
Dojindo Laboratories (Kumamoto, Japan).  The 
primers for real-time polymerase chain reaction 
(PCR) were synthesized at Nihon Gene Research 
Laboratories (Sendai, Japan), and Superscript II 
RNaseH(–) reverse transcriptase was purchased 
from Invitrogen (Carlsbad, CA).  Random hexam-
ers and oligo (dT) primers were purchased from 
Promega (Tokyo, Japan).
Cell culture
A cell pellet was suspended in Dulbecco’s modi-
ﬁed Eagle medium (DMEM; Gibco-BRL; Grand 
Island, NY), containing 200 U/mL penicillin G 
sodium (Gibco-BRL), 200 µg/mL streptomycin 
sulfate (Gibco-BRL), 0.25 µg/mL amphotericin B 
(Gibco-BRL) and 10% fetal bovine serum (FBS; 
JRH Bioscience, Lenexa, KS).  Incubation was 
performed in a humidiﬁed atmosphere of air/CO2 
(95:5) in an incubator maintained at 37˚C. The 
cells were subcultured in DMEM with 10% FBS, 
penicillin G sodium (200 U/mL), streptomycin 
sulfate (200 µg/mL) and amphotericin B (0.25 µg/
mL), and the medium was changed every 24 h.
Measurement of DNA synthesis and cell 
multiplication
Cell multiplication was measured by MTT assay. 
DNA synthesis was measured as the incorpora-
tion of BrdU into DNA.  Cells were plated in 
96-well plates at a density of 2 × 103 cells/well, 
4 × 103 cells/well, 8 × 103 cells/well or 16 × 103 
cells/well in DMEM with 15% FBS.  After 24 h, 
the cells were washed with phosphate buffered 
saline (PBS; Gibco-BRL) (pH 7.2) and placed in 
DMEM with 0.125% FBS for 6 h.  This medium 
was removed and the cells were placed in fresh 
DMEM with 0.125% FBS and BrdU (2 × 10–5 L/
well).  After 6 h of incubation with BrdU at 37˚C, 
the BrdU incorporated into DNA was measured 
by enzyme-linked immunosorbent assay (ELISA). 
After 2 h of incubation with the cell counting 
kit-8 solution (1 ×10–5 L/well), the absorbance of 
formosan, which is produced by WST-8 [2-(2-me-
thoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2, 
4-disulfophenyl)-2H-tetrazolium, monosodium 
salt], the main component of cell counting kit-8, 
was measured at 450 nm using microplate reader. 
Subsequent experiments were performed at 4 × 
103 cells/well.  The cells were plated in 96-well 
dishes at a density of 4 × 103 cells/well in DMEM 
with 15% FBS for 24 h.  After the cells were 
washed with PBS, they were placed in fresh 
DMEM with 0.125% FBS containing ET-1 or AT-
II at various concentrations (10–6 M, 10–8 M or 
10–10 M).  After 6 h of incubation with BrdU (2 
× 10–5 L/well) or cell counting kit-8 solution (1 × 
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10–5 L/well) at 37˚C, the BrdU uptake or formo-
san was measured.  To assess the effect of ETAR 
or ETBR on DNA synthesis and cell proliferation, 
the cells were incubated with ETAR antagonist 
BQ123 (10–6 M) or ETBR antagonist BQ788 (10–6 
M).
Expression of matrix related genes
Cell culture with ET-1 and AT-II
The cells were plated on 25 cm2 dishes at a densi-
ty of 4 × 103 cells/dish in DMEM containing 10% 
FBS.  After 48 h of culture, the cells were washed 
with PBS and placed in DMEM with 0.125% FBS 
for 12 h.  Cells were incubated for 12 h in fresh 
DMEM with 0.125% FBS containing ET-1 or AT-
II at various concentrations (0, 10–8 and 10–6 M), 
and the total RNA was extracted.  To assess the 
effect of ETAR or ETBR on expression of procol-
lagen α1 (I), transforming growth factor-beta1 
(TGF-β1), connective tissue growth factor (CTGF), 
tissue inhibitor of metalloproteinases-1 (TIMP-1), 
matrix metalloproteinase-13 (MMP-13), ET-1 and 
endothelin-converting enzyme (ECE) mRNA, 
the cells were incubated using BQ123 (10–6 M) or 
BQ788 (10–6 M) with ET-1 (10–6 M).
RNA isolation and reverse transcription
Total RNA of the conﬂuent CRL-2573 in 25 cm2 
dishes was extracted using the acid-phenol gua-
nidium method.  Total RNA (1 × 10–5 L) was re-
verse transcripted in a ﬁnal volume of 2 × 10–5 L 
containing 1× RT buffer (5 × 10–4 M each dNTP, 
3 × 10–3 M MgCl2, 7.5 × 10–2 M KCl, 5 × 10–2 
M Tris-HCl, pH 8.3), 10 units of Superscript II 
RNaseH(–) reverse transcriptase, 50 mg/ L ran-
dom hexamers 1 × 10–6 L, 1 × 10–7 M oligo (dT) 
primer 5 × 10–7 L.
Real-time PCR with light cycler system
We used real-time PCR to quantify mRNAs of 
procollagen α1 (I), TGF-β1, CTGF, TIMP-1, 
MMP-13, ET-1 and ECE mRNA.  Real-time 
PCR was performed using a Light Cycler System 
(Roche, Tokyo) and a Light Cycler-FastStart DNA 
Master SYBR Green I kit (Roche).  The appropri-
ate size of each PCR product was veriﬁed on an 
ethidium bromide-stained 3% agarose gel.  Con-
ditions for real-time PCR were as follows:  10 min 
denaturing at 95˚C, 10 s annealing at 55˚C, and 
3 s to 6 s ampliﬁcation at 72˚C.  Forty-ﬁve cycles 
were performed and then followed by melting-
curve analysis to verify the correctness of the 
amplification.  Amplification efficiency was de-
termined for all primer pairs.  The efﬁciency of 
the PCR was determined by analyzing a dilution 
series of control cDNA.  Using the analysis mode 
of the Light Cycler software package, the slope of 
log concentrations of the control cDNA dilutions 
was calculated.  Efﬁciency was calculated as fol-
lows:  Eff = 10–1/slope.
 The measured eff iciencies were used 
for the calculation of the mRNA values.  β2-
Microglobulin, a stable housekeeping gene in this 
cell system, was analyzed in parallel with every 
PCR.  The resulting β2-microglobulin values 
were used as the standard for the presentation of 
the mRNA data of the different transcriptions. 
Analysis of the data was performed according 
to the manufacturer’s instructions, using Light 
Cycler software version 3.5.3.  Oligonucleotide 
primers were designed according to the published 
sequences (Table 1).
Statistical analysis
Statistical analysis was performed using the Stat-
view Version 5.0 (SAS Institute, Cary, NC).  Sig-
niﬁcance was calculated using the unpaired t-test. 
Statistical signiﬁcance was regarded as P < 0.05.
Results
Effects of ET-1 and AT-II on DNA synthe-
sis and multiplication of CRL-2573 cells
In the cells, BrdU incorporation into DNA in-
creased with cell density:  1.04 ± 0.09 OD at 450 
nm at 2 × 103 cells/well, 1.51 ± 0.16 OD at 4 × 103 
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Fig. 1.  Reverse transcription-PCR.  Expressions of mRNA for AT-II type 1a receptor, 
ETAR and ETBR were found by 3% agarose gel electrophoresis.
cells/well, 1.81 ± 0.09 OD at 8 × 103 cells/well 
and 2.08 ± 0.06 OD at 16 × 103 cells/well.  Sub-
sequent experiments were performed at 4 × 103 
cells/well.  The expression of mRNA for the AT-
Table 1.  Primer nucleotide-sequence
β2-Microglobulin Forward primer  5'-CCGATGTATATGCTTGCAGAGTTAA-3'
 Reverse primer  5'-CAGATGATTCAGAGCTCCATAGA-3'
Procollagen α1( I ) Forward primer 5'-TCCGGCTCCTGCTCCTCTTA-3'
 Reverse primer  5'-GTATGCAGCTGACTTCAGGG-3'
Transforming growth factor-beta 1 (TGF-β1) Forward primer 5'-TTGCCCTCTACAACCAACAG-3'
 Reverse primer  5'-GGCTTGCGACCCACGTAGTA-3'
Connective tissue growth factor (CTGF) Forward primer  5'-TCCCTGCGACCCACACAA-3'
 Reverse primer  5'-TGCAACTGCTTTGGAAGGAC-3'
Tissue inhibitor of metalloproteinases-1 (TIMP-1) Forward primer  5'-TGCTCTTGTTGCTATCATTGATAGCTT-3'
 Reverse primer  5'-CGCTGGTATAAGGTGGTCTCGAT-3'
Matrix metalloproteinase-13 (MMP-13) Forward primer 5'-GGAAGACCCTCTTCTTCTCA-3'
 Reverse primer  5'-TCATAGACAGCATCTACTTTGTC-3'
Endothelin-1 (ET-1) Forward primer  5'-CAAGCTGGGAAAGAAGTGT-3'
 Reverse primer  5'-ATGTGCTCGGTTGTGTATC-3'
Endothelin-converting enzyme (ECE) Forward primer  5'-AGCTCTTCTTCCTGGGATT-3'
 Reverse primer 5'-CCAGACTTCGCATTTGTG-3'
Angiotensin-II (AT-II) type 1a receptor Forward primer  5'-TGTTCTGACCTTCTTGGATG-3'
 Reverse primer 5'-AAACACACTACGGAGCTTCT-3'
Endothelin A receptor (ETAR) Forward primer  5'-ACCAGTCGAAAAGCCTCA-3'
 Reverse primer 5'-TCTGCACAGGGTTAGTTCA-3'
Endothelin B receptor (ETBR) Forward primer  5'-AACTTCCGCTCGAGCAAT-3'
 Reverse primer 5'-TCCCGAGGCTTCATTCAT-3'
II type 1a receptor, for ETAR and for ETBR in 
mesangial cells was conﬁrmed by electrophoresis 
on 3% agarose gels (Fig. 1).  The addition of ET-1 
to CRL-2573 cells increased DNA synthesis by 
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20% at 10–10 M, 29% at 10–8 M and 33% at 10–6 
M (Fig. 2) and the number of cells by 2% at 10–10 
M, 4% at 10–8 M and 9% at 10–6 M (Fig. 3) in 
a dose-dependent manner.  AT-II did not affect 
DNA synthesis (–2% at 10–10 M, –2% at 10–8 M 
and 10% at 10–6 M) or multiplication (–2% at 
10–10 M, 0% at 10–8 M and –1% at 10–6 M) of 
Fig. 2.  Effects of ET-1 or AT-II on DNA synthesis of 
CRL-2573.  BrdU incorporation into DNA was mea-
sured in 4.0 × 103 cells/well over 6 h at various concen-
trations of ET-1 or AT-II. The mean value of absorbance 
for controls was set at 100%.  Data represent mean ± SD 
(8 wells).
Fig. 3.  Effects of ET-1 or AT-II on CRL-2573 multipli-
cation.  Cell number was measured in 4.0 × 103 cells/
well over 6 h at various concentrations of ET-1 or AT-II, 
using a cell count kit-8.  The mean value of absorbance 
for was set as 100%.  Data represent mean ± SD.
Fig. 4.  Effects of endothelin receptor antagonists on cell 
number of CRL-2573.  Cell number was measured in 4.0 
× 103 cells/well over 6 h at 10–6 M of ET-1.  The cells 
were treated with BQ123, ETAR antagonist, or BQ788, 
ETBR antagonist, at a concentration of 10–6 M in the 
presence of 10–6 M of ET-1.
CRL-2573 (Figs. 2 and 3).  The ETAR antagonist, 
BQ123 inhibited the ET-1 enhanced multiplica-
tion of CRL-2573 by 11%.  Similarly, the ETBR 
antagonist BQ788, inhibited the ET-1 enhanced 
multiplication of CRL-2573 by 8% (Fig. 4).
Effects of ET-1 and AT-II on mRNA expres-
sion of CRL-2573 cells
ET-1 at concentration of 10–8 M and 10– 6 M 
increased the expression of mRNA for procol-
lagen α1 (I) (1.27- to 1.57-fold), TGF-β1 (1.83- 
to 1.90-fold), TIMP-1 (1.60- to 1.80-fold) and 
MMP-13 (1.76- to 2.62-fold), compared with that 
of controls (Figs. 5a to e).  Meanwhile, AT-II 
had no affect on these mRNA expressions (Figs. 
5a to e).
 Both BQ123 and BQ788 suppressed the ET-1 
enhanced expression of mRNA for procollagen α1 
(I), TGF-β1 and MMP-13 by 54%, 73% and 74% 
respectively.  While, BQ123 completely blocked 
CTGF mRNA expression enhanced by ET-1, but 
BQ788 exerted no effect.  BQ123 did not affect 
the expression of mRNA for TIMP-1, but BQ788 
tended to suppress ET-1 enhanced TIMP-1 mRNA 
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expression (Table 2).  ET-1 at a concentration of 
10–6 M significantly increased ET-1 mRNA ex-
pression 1.77 fold and ECE mRNA expression 1.38 
fold, suggesting that it may mediate biological ac-
tion through an autocrine loop (Fig. 6).
Discussion
In this study, we investigated the expression 
of ETAR and ETBR in rat mesangial cells 
(CRL-2573).  ET-1 has been reported to promote 
the contraction, hypertrophy and proliferation of 
cells, and the synthesis of the extracellular matrix 
(Herman et al., 1998; Duan et al., 1999; Chen et 
al., 2001).  The addition of ET-1 to CRL-2573 
cells increased DNA synthesis and cell numbers, 
but the rates of increase were not very high.  ET-1 
stimulates mesangial cell proliferation in an au-
tocrine fashion as well as through the paracrine 
loop, where our data indicates that ET-1 increased 
the expression of ET-1 and ECE.  The proliferat-
ing effects of ET-1 in mesangial cells are primari-
ly via ETAR (Benigni, 2000; Hocher et al., 2003), 
although there are data suggesting that ETBR me-
diates human mesangial cell proliferation (Herman 
et al., 1998; Benigni, 2000).  In the present study, 
although antagonist administration apparently did 
not change DNA synthesis, the administration of 
the ETAR antagonist suppressed cell prolifera-
tion, strongly suggesting that ETAR mediates cell 
proliferation.  More interestingly, the addition of 
ET-1 also increased the expression of mRNA for 
ET-1 and ECE, suggesting that ET-1 functions in 
an autocrine and paracrine manner.  This indi-
cates that much higher levels of locally produced 
ET-1 than those in circulating plasma promote tis-
sue ﬁbrosis.
 A major role of ET-1 in mediating renal ﬁ-
brosis has recently been pointed out.  Antagonism 
of ET-1 receptors delayed the evolution of renal 
failure and increased survival rate in rats with 
renal mass reduction (Hocher et al., 2003; Boffa 
et al., 2001; Goddard et al., 2004).  Moreover, the 
use of an endothelin receptor antagonist improved 
Fig. 5.  Effects of ET-1 or AT-II on CRL-2573 matrix-
related gene expression.  The expressions of mRNA for 
procollagen α1 (I) (a), TGF-β1 (b), CTGF (c), TIMP-1 (d) 
and MMP-13 (e) were determined by real-time quantita-
tive PCR.  Data were normalized to β2-microglobulin 
mRNA levels.  Error bars represent mean ± SD of 4 in-
dependent experiments.
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renal structural damage and reduced extracellular 
matrix formation (Benigni, 2000; Boffa et al., 
2001; Hocher et al., 2003; Chade et al., 2003).  In 
the present study, ET-1 increased procollagen α1 
(I) gene expression in a dose-dependent manner. 
In addition, ET-1 dose-dependently increased the 
expression of TGF-β1, as well as CTGF.  TGF-β1 
promotes fibroblast proliferation and increases 
extracellular matrix production (Gomez-Garre et 
Table 2.  Effects of ET-1 and endothelin receptor antagonist on CRL-2573 matrix-related gene ex-
pression
     mRNA Control ET-1 (10–6 M) ET-1 (10–6 M)   
  BQ123 (10–6 M)  BQ788 (10–6 M)
Procollagen α1 (I) 1.01 ± 0.23 2.16 ± 0.17 1.18 ± 0.24 0.91 ± 0.17
TGF-β1 0.52 ± 0.25 1.02 ± 0.22 0.75 ± 0.09 0.68 ± 0.27
CTGF 0.19 ± 0.08 0.36 ± 0.04  0.19 ± 0.08 0.29 ± 0.19
TIMP-1 0.35 ± 0.11 1.53 ± 0.09 1.57 ± 0.12 1.22 ± 0.23
MMP-13 0.51 ± 0.16 0.95 ± 0.15 0.70 ± 0.16 0.71 ± 0.12
Data are mean ± SD of 4 independent experiments.
Each mRNA was normalized to β2-microglobulin mRNA.
Fig. 6.  Effects of ET-1 on ET-1 and ECE transcript lev-
els of CRL-2573.  The expressions of mRNA for ET-1 
and ECE were determined by real-time PCR.  The data 
were normalized by β2-microglobulin mRNA.  Error 
bars represent mean ± SD of four independent experi-
ments.
al., 1996; Boffa et al., 2003; Sorokin and Kohan, 
2003).  TGF-β1 is thought to play a central role in 
the progression of renal ﬁbrosis.  CTGF is located 
downstream from TGF-β1 and acts proﬁbrogeni-
cally.  As clearly indicated in these ﬁndings, ET-1 
increases the production of the collagen-syn-
thesizing system.  According to one study, ET-1 
increases the expression of the fibronectin and 
procollagen α1 (I) and (IV) genes in mesangial 
cells (Gomez-Garre et al., 1996).  ET-1 also in-
creased the collagen-degrading system inhibitor 
TIMP-1, suggesting that collagen degradation 
may be inhibited, thereby promoting ﬁbrosis, al-
though increased MMP-13 mRNA gene expres-
sion was observed.
 In rat models of mesangial proliferative 
glomerular nephritis, ETAR blocker reduced 
mesangial cell proliferation, and bosentan 
(ETAR/ETBR blocker) improved renal function 
and reduced mesangial cell ET-1 mRNA levels. 
There is abundant evidence in vivo that ET-1 an-
tagonists ameliorate glomerular injury in animal 
models with diabetic nephropathy (Nakamura 
et al., 1995; Benigni, 2000).  Bosentan reduced 
albuminuria, increased glomerular filtration 
P < 0.01
P < 0.05
P < 0.05
P < 0.05
P < 0.05
P < 0.05
P < 0.05
P < 0.05
P < 0.05
P < 0.05
P < 0.01
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rate and ameliorated the mesangial matrix in 
diabetic rats (Benigni et al., 1998, 2000).  Our 
ﬁndings also indicated that the increased expres-
sion of procollagen α1 (I) induced by ET-1 was 
attenuated by both ETAR and ETBR blockers 
(BQ123 and BQ788).  However, the ET-1 en-
hanced expression of TGF-β1 and TIMP-1 was 
reduced by ETBR blocker.  The causes of these 
receptor-related differences are not clear.  Since 
nephropathy is improved by the administration 
of ETAR antagonists, ETAR has been consid-
ered responsible.  As the data we obtained in the 
present study suggest, ETBR is also involved 
in increased production of ECM.  These results 
may reflect our culture conditions for the cell 
line CRL-2573, necessitating further study.  To 
use ET-1 antagonists as therapeutic agents, it is 
necessary to compare the effects of an ETAR an-
tagonist and a combination of ETAR and ETBR 
antagonists.
 On the other hand, the addition of AT-II did 
not change the cell growth or the gene expression 
of procollagen α1 (I) or TGF-β1, although the 
expression of AT-II type 1a receptor mRNA was 
observed in the cell line.  Therefore, there may 
be abnormalities in the receptors or the signal 
transduction system, and this cell line would not 
be suitable for the study of the angiotensin sys-
tem.
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